Epigenomics to file "improved" colon cancer blood test in US by year-end
This article was originally published in Clinica
Executive Summary
Epigenomics is developing a next-generation version of its colorectal cancer blood test, Epi proColon, which it hopes to file with the US FDA by the end of the year.